Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs

International Journal of Drug Policy

Volumn 26, Issue 10, 2015, Pages 893-898

  Grebely, Jason ^a,f   Bruggmann, Philip ^b   Treloar, Carla ^c   Byrne, Jude ^d   Rhodes, Tim ^e   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Arud Centres for Addiction Medicine   (Switzerland)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d International Network of People Who Use Drugs   (Australia)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Australian Injecting and Illicit Drug Users League   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DASABUVIR; INTERFERON; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; AUSTRALIA; CLINICAL TRIAL (TOPIC); DISEASE SURVEILLANCE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; ELASTOGRAPHY; HARM REDUCTION; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CENTER; HEALTH PROGRAM; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION CONTROL; INTEGRATED HEALTH CARE SYSTEM; INTRAVENOUS DRUG ABUSE; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PEER GROUP; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; PRISON; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); UNITED STATES; VIRUS TRANSMISSION; COMORBIDITY; COMPLICATION; HEALTH CARE DELIVERY; SUBSTANCE ABUSE;

COMORBIDITY; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84941810742     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.07.007     Document Type: Editorial

References (58)

1. AASLD/IDSA Recommendations for testing, managing, and treating hepatitis C 2015, Retrieved January 18 2015 from 〈www.hcvguidelines.org〉.
2. Alavi M., Raffa J.D., Deans G.D., Lai C., Krajden M., Dore G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 2014, 34:1198-1206.
3. Aspinall A., Corson S., Doyle J., Grebely J., Hutchinson S., Dore G.J., et al. Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 2013, 57(S2):S80-S89.
4. Aspinall E.J., Weir A., Sacks-Davis R., Spelman T., Grebely J., Higgs P., et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. International Journal of Drug Policy 2014, 25:179-182.
5. Barua S., Greenwald R., Grebely J., Dore G.J., Swan T., Taylor L.E. Restrictions for medicaid reimbursement of Sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine 2015, [Epub ahead of print]. 10.7326/M15-0406.
6. Binford M.C., Kahana S.Y., Altice F.L. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Current HIV/AIDS Reports 2012, 9:287-312.
7. Bruggmann P., Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 2015, 26(Suppl 1):S22-S26.
8. Bruggmann P., Litwin A.H. Models of care for the management of HCV among people who use drugs: One size does not fit all. Clinical Infectious Diseases 2013, 57(S2):S80-S89.
9. Crawford S., Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clinical Infectious Diseases 2013, 57(Suppl 2):S75-S79.
10. Cullen B.L., Hutchinson S.J., Cameron S.O., Anderson E., Ahmed S., Spence E., et al. Identifying former injecting drug users infected with hepatitis C: An evaluation of a general practice-based case-finding intervention. Journal of Public Health (Oxford) 2012, 34:14-23.
11. de Vos A.S., Prins M., Kretzschmar M.E. Hepatitis C Virus treatment as prevention among injecting drug users: Who should we cure first?. Addiction 2015, 110(6):975-983. 10.1111/add.12842.
12. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. Lancet 2010, 376:285-301.
13. Dimova R.B., Zeremski M., Jacobson I.M., Hagan H., Des Jarlais D.C., Talal A.H. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 2013, 56:806-816.
14. Drainoni M.L., Litwin A.H., Smith B.D., Koppelman E.A., McKee M.D., Christiansen C.L., et al. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. American Journal of Public Health 2012, 102:e115-e121.
15. European Association for Study of Liver EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 2014, 60:392-420.
16. Foucher J., Reiller B., Jullien V., Leal F., di Cesare E.S., Merrouche W., et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: A prospective study. Journal of Viral Hepatitis 2009, 16:121-131.
17. Grebely J., Dore G.J. What is killing people with hepatitis C virus infection?. Seminars in Liver Disease 2011, 31:331-339.
18. Grebely J., Genoway K., Khara M., Duncan F., Viljoen M., Elliott D., et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal of Drug Policy 2007, 18:437-443.
19. Grebely J., Matthews G.V., Lloyd A.R., Dore G.J. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements. Clinical Infectious Diseases 2013, 57:1014-1020.
20. Grebely J., Tyndall M.W. Management of HCV and HIV infections among people who inject drugs. Current Opinion in HIV and AIDS 2011, 6:501-507.
21. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. The Journal of Infectious Diseases 2011, 204:74-83.
22. Hagan H., Pouget E.R., Des Jarlais D.C., Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place. American Journal of Epidemiology 2008, 168:1099-1109.
23. Hajarizadeh B., Grebely J., Dore G.J. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology & Hepatology 2013, 10:553-562.
24. Harris M., Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal 2013, 10:7.
25. Harris M., Rhodes T., Martin A. Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. Social Science & Medicine 2013, 83:19-26.
26. Hellard M., Rolls D.A., Sacks-Davis R., Robins G., Pattison P., Higgs P., et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 2014, 60:1861-1870.
27. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 2009, 49:561-573.
28. Iversen J., Grebely J., Topp L., Wand H., Dore G., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. Journal of Viral Hepatitis 2014, 21:198-207.
29. ® 2014.
30. Keats J., Micallef M., Grebely J., Hazelwood S., Everingham H., Shrestha N., et al. Assessment and delivery of treatment for hepatitis C virus infection in the opioid substitution treatment setting with integrated peer-based support. International Journal of Drug Policy 2015, 26:999-1006.
31. Lalezari J., Sullivan J.G., Varunok P., Galen E., Kowdley K.V., Rustgi V., et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology 2015, 63:364-369.
32. Litwin A.H., Smith B.D., Drainoni M.L., McKee D., Gifford A.L., Koppelman E., et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Digestive and Liver Disease 2012, 44:497-503.
33. MacArthur G.J., van Velzen E., Palmateer N., Kimber J., Pharris A., Hope V., et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. International Journal of Drug Policy 2014, 25:34-52.
34. Mangia A., Kugelmas M., Everson G.T., Hinestrosa F., Ma J., McNally J., et al. Virologic response rates to Sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: A retrospective analysis of Phase 3 data. Hepatology 2013, 58:752A.
35. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
36. Martin N.K., Hickman M., Hutchinson S.J., Goldberg D.J., Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 2013, 57(Suppl 2):S39-S45.
37. Martin N.K., Vickerman P., Foster G.R., Hutchinson S.J., Goldberg D.J., Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology 2011, 54:1137-1144.
38. Martin N.K., Vickerman P., Grebely J., Hellard M., Hutchinson S.J., Lima V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013, 58:1598-1609.
39. Masson C.L., Delucchi K.L., McKnight C., Hettema J., Khalili M., Min A., et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. American Journal of Public Health 2013, 103:e81-e88.
40. Moessner B.K., Jorgensen T.R., Skamling M., Vyberg M., Junker P., Pedersen C., et al. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 2011, 106:970-976.
41. Neale J., Tompkins C., Sheard L. Barriers to accessing generic health and social care services: A qualitative study of injecting drug users. Health Soc Care Community 2008, 16:147-154.
42. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378:571-583.
43. Nolan S., Dias Lima V., Fairbairn N., Kerr T., Montaner J., Grebely J., et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014, 109:2053-2059.
44. Ostertag S., Wright B.R.E., Broadhead R.S., Altice F.L. Trust and other characteristics associated with health care utilization by injection drug users. Journal of Drug Issues 2006, 36:953-974.
45. Page K., Morris M.D., Hahn J.A., Maher L., Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: Using evidence to inform comprehensive prevention. Clinical Infectious Diseases 2013, 57(Suppl 2):S32-S38.
46. ® 2014.
47. Robaeys G., Grebely J., Mauss S., Bruggmann P., Moussalli J., De Gottardi A., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clinical Infectious Diseases 2013, 57(Suppl 2):S129-S137.
48. Roose R.J., Cockerham-Colas L., Soloway I., Batchelder A., Litwin A.H. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. Journal of Health Care for the Poor and Underserved 2014, 25(2):652-662.
49. Strathdee S.A., Latka M., Campbell J., O'Driscoll P.T., Golub E.T., Kapadia F., et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases 2005, 40(Suppl 5):S304-S312.
50. Treloar C., Rance J., Dore G.J., Grebely J. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. Journal of Viral Hepatitis 2014, 21(8):560-567.
51. Treloar C., Rance J., Bath N., Everingham H., Micallef M., Day C., et al. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy 2015, 26:992-998.
52. Tsui J.I., Evans J.L., Lum P.J., Hahn J.A., Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Internal Medicine 2014, 174:1974-1981.
53. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 2011, 106:1978-1988.
54. van den Berg C.H., Smit C., Bakker M., Geskus R.B., Berkhout B., Jurriaans S., et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. European Journal of Epidemiology 2007, 22:183-193.
55. Wang L., Wei X., Wang X., Li J., Li H., Jia W. Long-term effects of methadone maintenance treatment with different psychosocial intervention models. PLoS ONE 2014, 9:e87931.
56. White B., Dore G.J., Lloyd A.R., Rawlinson W.D., Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study. Medical Journal of Australia 2014, 201:326-329.
57. WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection 2014, World Health Organization, Geneva, Switzerland.
58. Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K.J., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention. PLoS ONE 2014, 9:e103345.